# The DAWN Antivirals Trial for Ambulatory COVID-19 Patients

> **NCT04730206** · PHASE3 · TERMINATED · sponsor: **KU Leuven** · enrollment: 44 (actual)

## Conditions studied

- Covid19
- SARS-CoV Infection

## Interventions

- **DRUG:** Camostat
- **DRUG:** Placebo
- **DRUG:** Molnupiravir

## Key facts

- **NCT ID:** NCT04730206
- **Lead sponsor:** KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-15
- **Primary completion:** 2022-07-13
- **Final completion:** 2022-07-13
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** recruitment was too slow
- **Last updated:** 2022-10-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04730206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04730206, "The DAWN Antivirals Trial for Ambulatory COVID-19 Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04730206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*